JP2017527567A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527567A5
JP2017527567A5 JP2017512976A JP2017512976A JP2017527567A5 JP 2017527567 A5 JP2017527567 A5 JP 2017527567A5 JP 2017512976 A JP2017512976 A JP 2017512976A JP 2017512976 A JP2017512976 A JP 2017512976A JP 2017527567 A5 JP2017527567 A5 JP 2017527567A5
Authority
JP
Japan
Prior art keywords
formulation
preparation
formula
compound
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/050785 external-priority patent/WO2016044649A1/en
Publication of JP2017527567A publication Critical patent/JP2017527567A/ja
Publication of JP2017527567A5 publication Critical patent/JP2017527567A5/ja
Pending legal-status Critical Current

Links

JP2017512976A 2014-09-17 2015-09-17 癌の治療のための注射製剤 Pending JP2017527567A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051904P 2014-09-17 2014-09-17
US62/051,904 2014-09-17
PCT/US2015/050785 WO2016044649A1 (en) 2014-09-17 2015-09-17 Injectable formulations for treating cancer

Publications (2)

Publication Number Publication Date
JP2017527567A JP2017527567A (ja) 2017-09-21
JP2017527567A5 true JP2017527567A5 (enExample) 2018-10-25

Family

ID=55533871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512976A Pending JP2017527567A (ja) 2014-09-17 2015-09-17 癌の治療のための注射製剤

Country Status (6)

Country Link
US (3) US20170290765A1 (enExample)
EP (1) EP3193879A4 (enExample)
JP (1) JP2017527567A (enExample)
AU (1) AU2015317509A1 (enExample)
CA (1) CA2960287A1 (enExample)
WO (1) WO2016044649A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039839A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
EP2968387A4 (en) 2013-03-15 2017-04-05 Epizyme, Inc. Methods of synthesizing substituted purine compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
JP2006199588A (ja) * 2003-05-06 2006-08-03 Senju Pharmaceut Co Ltd オキサゾリジノン誘導体含有水性液剤
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
WO2008088816A1 (en) * 2007-01-18 2008-07-24 Pgxhealth, Llc Adenosine derivative formulations for medical imaging
RU2470636C2 (ru) * 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
EP2629775A4 (en) * 2010-10-18 2014-06-11 Dainippon Sumitomo Pharma Co INJECTABLE FORMULATION WITH DELAYED RELEASE
BR112013013659B8 (pt) * 2010-12-03 2024-02-27 Epizyme Inc Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
US20150284422A1 (en) * 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
WO2014039839A1 (en) * 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
CA2894220A1 (en) * 2012-12-21 2014-06-26 Epizyme, Inc. Dot1l inhibitors for use in the treatment of leukemia
JP2016513699A (ja) * 2013-03-15 2016-05-16 エピザイム,インコーポレイティド 癌の治療のための注射製剤

Similar Documents

Publication Publication Date Title
AU2013377736B2 (en) Oral antiseptic composition for treating oral mucositis
JP2011102304A5 (enExample)
JP2016515628A5 (enExample)
CN105555276A (zh) 作为治疗病毒性感染的药剂的贝前列素异构体
JP2012521435A5 (enExample)
JP2018513188A5 (enExample)
CA3019769C (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
JP2011503044A5 (enExample)
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
JP2019518798A (ja) リポヌクレオチドに基づくardsの治療
JP2015517523A5 (enExample)
JP2017527567A5 (enExample)
JP2016512818A5 (enExample)
RU2015119377A (ru) Лекарственные формы леводопы для быстрого купирования болезни паркинсона
JP2014148552A5 (enExample)
JP2016505050A5 (enExample)
JP2008533135A (ja) ゲムシタビン誘導体の経口投薬形態
JP2020510043A5 (enExample)
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
CN109758452A (zh) 胺类化合物治疗疼痛的医药用途
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
JP2023511319A (ja) がんを調節するための組成物および方法
CN110638802A (zh) Atca在制备治疗肿瘤的药物中的用途
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.